Janssen announced US FDA approval of Invega Hayfera, the first and only twice-yearly treatment for adults with schizophrenia.
List view / Grid view
KarXT significantly reduced both positive and negative of symptoms of schizophrenia without the common problematic side effects of current antipsychotic therapies.
According to Jazz Pharmaceuticals, the combined company will be a leader in neuroscience, well positioned to maximise the value of its diversified portfolio.
A team has created a nasal spray as a drug delivery system to get schizophrenia medication directly to the brain.
A single dose of CVN058 was able to normalise brainwaves being used as a biomarker for cognitive impairment associated with schizophrenia.
The EMA's human medicines committee has adopted a positive opinion for eight medicines, recommending their marketing authorisation.
The regulatory body has issued guidance based on a complaint that stated a precipitate formed in Aripiprazole 1mg/ml oral solution.
Side effects revealed during post-marketing experience are not listed on Atrolak XL prolonged-release tablet patient information leaflets, announces the MHRA.
Heritage has recalled two of its injectable treatments after microbial growths were found.
Novel regimen enables physicians to fully dose up to two months of Aristada treatment on day one...
Children with intellectual difficulty or autism are more likely to be given antipsychotic medication from a younger age than those without intellectual disability...
Brazilian researchers combine mass spectrometry, 2-D liquid chromatography and ion mobility to identify over 10,000 proteins in brain cells possibly involved in schizophrenia.
The FDA has approved the first drug in the U.S. with a digital ingestion tracking system that records that the medication was taken...
The FDA has approved the supplemental New Drug Application for Vraylarfor the maintenance treatment of adults with schizophrenia...